NCT04736901View on ClinicalTrials.gov

Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19

CompletedOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

October 1, 2021

Study Completion Date

December 1, 2021

Conditions
Covid19Corona Virus InfectionHypercoagulability
Interventions
DRUG

Enoxaparin

0.5 mg/kg every 12 hours

DRUG

Enoxaparin

40 mg/day

DRUG

Rivaroxaban

10 mg once daily

DRUG

Rivaroxaban

20 mg once daily

DRUG

Apixaban

2.5 mg twice daily

DRUG

Apixaban

5 mg twice daily

Trial Locations (1)

11314

Teachers Hospital, Cairo

All Listed Sponsors
collaborator

Misr International University

OTHER

lead

Ain Shams University

OTHER

NCT04736901 - Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19 | Biotech Hunter | Biotech Hunter